MonoSol Rx signs agreement with Hikma for thin film products in the Middle East

Published: 18-Dec-2008
Regulatory Research & Development

MonoSol Rx has entered into an agreement for thin film pharmaceutical products with Hikma Pharmaceutical, a manufacturer of generic and in-licensed pharmaceutical products.


MonoSol Rx has entered into an agreement for thin film pharmaceutical products with Hikma Pharmaceutical, a manufacturer of generic and in-licensed pharmaceutical products.

MonoSol Rx is the developer of PharmFilm technology and a drug delivery company specialising in dissolving thin film pharmaceutical products.

Under terms of the agreement, Hikma will exclusively distribute in the Middle East three products based on PharmFilm technology. Hikma will obtain all registrations and approvals required to market the products throughout the region.

MonoSol Rx will receive milestone payments and payments for the purchase of product supply.

Mark Schobel, president and chief executive of MonoSol Rx, said: "In addition to expanding our reach into new geographic territories, our partnership with Hikma further validates our proprietary PharmFilm technology, leadership in thin film drug development, and growing intellectual property portfolio."

  • Companies:
  • Hikma Pharmaceuticals
  • MonoSol Rx
See more

You may also like

Regulatory

Status update on ANDA for generic Advair Diskus (VR315 [US])

Read more
Vectura Group, an industry leading inhalation CDMO, confirms the announcement made by its partner Hikma Pharmaceuticals

Trending Articles

  1. IMed supports K2 medical systems in their EU MDR transition Consultancy firm helps K2 navigate the complex regulatory process to achieve Article 97 compliance
  2. Cleancube multi: Guardtech’s container facilities support NHS aseptic pharmacies Award-winning mobile cleanrooms offer fast, flexible solutions for facility upgrades
  3. Ardena's Oss nanomedicine facility gains full GMP approval from the Dutch Healthcare Authority The pharmaceutical manufacturing facility can produce advanced nanoparticle drug delivery systems, including lipid-based, polymeric and metal oxide nanoparticles
  4. Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
  5. Syndax Pharmaceuticals' leukaemia drug Revuforj bags FDA approval The therapeutic is the first and only menin inhibitor to gain FDA approval for acute relapsed or refractory acute leukaemia

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Regulatory

Status update on ANDA for generic Advair Diskus (VR315 [US])

Vectura Group, an industry leading inhalation CDMO, confirms the announcement made by its partner Hikma Pharmaceuticals
Regulatory

Hikma launches Dalfampridine Extended-release tablets

Hikma Pharmaceuticals, formerly known as West-Ward Pharmaceuticals, has launched Dalfampridine Extended-release tablets, 10 mg, the generic therapeutic equivalent to Ampyra
Regulatory

Hikma enters settlement agreement with Jazz for sodium oxybate

Jazz will grant Hikma and West-Ward the right to sell an authorised generic of Xyrem in the US
Research & Development

Blood cancer charity thanks Hikma Pharmaceuticals for its support

DKMS is dedicated to the fight against blood cancer, recruiting stem cell donors and providing second chances at life
Manufacturing

Hikma announces successful resolution to FDA warning letter at its Portugal facility

Will enable Hikma to accelerate the introduction of new products to the market
Regulatory

Hikma receives warning letter from US FDA

Over environmental monitoring issues at its plant in Portugal
Research & Development

MidaSol Therapeutics signs research collaboration with major US pharmaceutical company

Midatech and MonoSol Rx joint venture to develop new treatment for diabetes
Subscribe now